{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Solid+Tumors", "query": { "condition": "HER2-positive Solid Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 102, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-positive+Solid+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:31:58.306Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT00927589", "title": "A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2009-07", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2015-12-10", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00927589" }, { "nct_id": "NCT02965885", "title": "A Study of TAS-116 in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "TAS-116", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2017-07-10", "completion_date": "2019-05-03", "has_results": false, "last_update_posted_date": "2024-09-04", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Greenville, South Carolina • Fairfax, Virginia", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02965885" }, { "nct_id": "NCT05593094", "title": "A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "ZN-A-1041", "type": "DRUG" }, { "name": "ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b", "type": "DRUG" }, { "name": "ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b", "type": "DRUG" }, { "name": "ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b", "type": "DRUG" }, { "name": "ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c", "type": "DRUG" }, { "name": "ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c", "type": "DRUG" }, { "name": "ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2020-09-03", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 8, "location_summary": "Tucson, Arizona • Cerritos, California • San Francisco, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05593094" }, { "nct_id": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Colorectal Cancer", "HER2-positive Gastroesophageal Cancer", "HER2-positive Endometrial Cancer" ], "interventions": [ { "name": "BDC-1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bolt Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2020-02-24", "completion_date": "2025-02-14", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 11, "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278144" }, { "nct_id": "NCT00773344", "title": "Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • New York, New York", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00773344" }, { "nct_id": "NCT07124000", "title": "DESTINY-PANTUMOUR04", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma (NOS)", "Anal Cancer", "Bladder Cancer", "Cervical Cancer", "Endometrial Cancer", "Esophageal Cancer", "Gall Bladder Cancer", "Gastrointestinal Stromal Tumour", "Head and Neck Cancer", "Liver Cancer", "Melanoma", "Mouth Cancer", "Nasopharangeal Cancer", "Neuroendocrine, Gastrointestinal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cell Carcinoma", "Salivary Gland Cancer", "Sarcoma", "Small Cell Lung Cancer", "Testicular Cancer", "Throat Cancer", "Thyroid Cancer", "Urethral Cancer", "Vaginal Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 100, "start_date": "2025-09-18", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bullhead City", "state": "Arizona" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07124000" }, { "nct_id": "NCT03650348", "title": "PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2-positive Bladder Cancer", "HER2-positive Solid Tumor" ], "interventions": [ { "name": "PRS-343 in Combination with Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pieris Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-08-21", "completion_date": "2022-08-11", "has_results": false, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650348" }, { "nct_id": "NCT04316169", "title": "Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Hydroxychloroquine 200 mg", "type": "DRUG" }, { "name": "Faslodex", "type": "DRUG" }, { "name": "Anastrazole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Hydroxychloroquine 400 mg", "type": "DRUG" }, { "name": "Hydroxychloroquine 600 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-21", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2022-12-23", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04316169" }, { "nct_id": "NCT04561362", "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasm", "Triple Negative Breast Neoplasms", "Hormone Receptor Positive, HER2-negative Neoplasms", "Hormone Receptor Positive, HER2-low Neoplasms", "Breast Neoplasms", "Non-Small-Cell Lung Neoplasms", "Ovarian Neoplasm", "Advanced Solid Tumor" ], "interventions": [ { "name": "BT8009", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BicycleTx Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-07-17", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-05-21T22:31:58.306Z", "location_count": 9, "location_summary": "Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04561362" } ] }